196204-01-0 Usage
General Description
4-Piperidin-4-yl-benzoic acid, also known as 4-(4-Piperidinyl)benzoic acid, is a type of chemical compound with a molecular formula of C12H15NO2. 4-Piperidin-4-yl-benzoic acid, which belongs to the class of organic compounds known as benzoic acids, is characterized by a benzoic acid (or its derivatives) group connected to an organooxygen compound. Judging by the name, it's evident that the structure contains a piperidine ring, which is a common chemical structure in many pharmaceutical drugs. 4-Piperidin-4-yl-benzoic acid is typically used in scientific research, including pharmaceutical research. However, there's limited information available regarding its specific applications and its effects on human health and the environment.
Check Digit Verification of cas no
The CAS Registry Mumber 196204-01-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,9,6,2,0 and 4 respectively; the second part has 2 digits, 0 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 196204-01:
(8*1)+(7*9)+(6*6)+(5*2)+(4*0)+(3*4)+(2*0)+(1*1)=130
130 % 10 = 0
So 196204-01-0 is a valid CAS Registry Number.
InChI:InChI=1/C12H15NO2/c14-12(15)11-3-1-9(2-4-11)10-5-7-13-8-6-10/h1-4,10,13H,5-8H2,(H,14,15)
196204-01-0Relevant articles and documents
BENZO- AND PYRIDO-PYRAZOLES AS PROTEIN KINASE INHIBITORS
-
Page/Page column 28, (2020/10/28)
The invention relates to new chemical compounds of Formula (I), pharmaceutical compositions containing them, and their use for the pharmacological treatment of a cancer, preferably a glioblastoma.
CYSTEINE PROTEASE INHIBITORS
-
Page/Page column 85-86, (2010/11/25)
-
SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL) BENZOHETEROARYL COMPOUNDS
-
, (2008/06/13)
This invention is directed to an (aminoiminomethyl or aminomethyl) benzoheteroaryl compound of formula I which is useful for inhibiting the activity of Factor Xa by combining said compound with a composition containing Factor Xa. The present invention is also directed to compositions containing compounds of the formula I, methods for their preparation, their use, such as in inhibiting the formation of thrombin or for treating a patient suffering from, or subject to, a disease state associated with a physiologically detrimental excess amount of thrombin.